Preoperative Glycosylated Haemoglobin (HbA1c) Does Impact on Postoperative Complications in Patients Undergoing Gastrointestinal and Hepatobiliary Surgery.
The impact of preoperative glycated haemoglobin (HbA1c) in patients undergoing gastrointestinal and hepatobiliary surgery is unclear as data is limited. Patients undergoing gastrointestinal surgery attending pre-assessment screening (PAS) clinics from August to September 2016 at the Queen Elizabeth Hospital Birmingham (QEHB) were identifi ed. Outcome measure was postoperative complications as defi ned by the Clavien-Dindo classifi cation system. In this study, 381 patients were included, of which 48% (181/381) had HbA1c measured. Of these, 27% (49/181) had a HbA1c ≥ 48 mmol/mol. Overall complications were 14% and major complication rates were 3% (11/381). In unadjusted models, patients with HbA1c ≥ 48 mmol/mol had signifi cantly higher rates of overall complications (odds ratio [OR] = 2.82, 95% confi dence interval [CI] = 1.22-6.49; p = 0.015). In adjusted models, only surgical grade was predictive of overall complications. In patients undergoing major surgery (n = 93), there were signifi cantly higher rates of overall complications in patients with HbA1c ≥ 48 mmol/mol as compared to those with HbA1c < 48 mmol/mol (63% vs. 46%, p = 0.043). Utility of HbA1c to stratify patients undergoing gastrointestinal and hepatobiliary surgery into high-risk clinics is limited from this study. Future studies should aim to validate these fi ndings in much larger cohorts.